631911-38-1Relevant articles and documents
A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s
Subasinghe, Nalin L.,Travins, Jeremy M.,Ali, Farah,Huang, Hui,Ballentine, Shelley K.,Marugan, Juan Jose,Khalil, Ehab,Hufnagel, Heather R.,Bone, Roger F.,Desjarlais, Renee L.,Crysler, Carl S.,Ninan, Nisha,Cummings, Maxwell D.,Molloy, Christopher J.,Tomczuk, Bruce E.
, p. 2200 - 2204 (2007/10/03)
Inhibiting the classical pathway of complement activation by attenuating the proteolytic activity of the serine protease C1s is a potential strategy for the therapeutic intervention in disease states such as hereditary angioedema, ischemia-reperfusion inj
NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS
-
Page 352-353, (2010/02/05)
Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.
